While the Overweight rating suggests that JP Morgan's analyst believes ITeos Therapeutics has a good potential to outperform the market or its sector, the reduction in the price target could imply a tempering of growth expectations or a response to market conditions. This mixed signal may lead to a neutral short-term impact on the stock price as investors digest both the continued positive rating and the lowered price target.